Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib + ruxolitinib versus placebo + ruxolitinib in JAK inhibitor-naive myelofibrosis
NL-OMON56000Phase 3Not yet recruiting
- Sponsor
- Constellation Pharmaceuticals
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Pelabresib + ruxolitinib with Placebo + ruxolitinib (2 arms). Primary endpoint: Splenic response at Week 24. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
pelabresibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON56000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56000.